Capricor Therapeutics is expected to release data from the phase 3 HOPE-3 trial in Q3'25, thus presenting a potential path ...

The newly recommended dosing schedule significantly lowered ARIA-E rates compared to the original dosing schedule, adding to ...

Panelists discuss how transitioning patients from intravenous (IV) to subcutaneous (SubQ) therapies demands a coordinated, multidisciplinary approach—integrating clinical judgment, electronic medical ...

I’ve endured numerous rounds of radiation and taken thousands of pills—but CAR-T is the most effective therapy I’ve completed ...

Prime Medicine, Inc. achieved strong early data in CGD with PM359, surpassing efficacy thresholds. Click here to find out why ...

The newly recommended dosing schedule significantly lowered ARIA-E rates compared to the original dosing schedule, adding to the established safety profile of the treatment INDIANAPOLIS, ...

The FDA has approved Gammagard Liquid ERC as a replacement therapy for PI in adult and pediatric patients 2 years of age and older.

Panelists discuss how the rise of patient awareness around subcutaneous (SubQ) therapies calls for empathetic, evidence-based education, shared decision-making, and seamless system integration to ...

Abbvie (($CC:ABBV.CUR)) announced an update on their ongoing clinical study. AbbVie has launched an Expanded Access Program ...

At a lymphoma conference, experts sparred about treatment options, while an outside expert highlighted the value of each approach.

Shefali Jariwala died following a suspected cardiac arrest.

Morquio Syndrome, or Mucopolysaccharidosis Type IV (MPS IV), is a rare genetic disorder causing glycosaminoglycans (GAGs) buildup due to enzyme deficiencies, leading to severe skeletal and organ ...